| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A model of the economic benefits of global hepatitis C elimination: an investment case
|
Scott, Nick
|
|
|
5 |
10 |
p. 940-947
|
artikel
|
| 2 |
Axing of Public Health England: disease prevention in limbo
|
The Lancet Gastroenterology & Hepatology,
|
|
|
5 |
10 |
p. 875
|
artikel
|
| 3 |
Clinical research: further COVID-19 collateral damage
|
The Lancet Gastroenterology & Hepatology,
|
|
|
5 |
10 |
p. 875
|
artikel
|
| 4 |
Do the most heavily burdened countries have the right policies to eliminate viral hepatitis B and C?
|
Palayew, Adam
|
|
|
5 |
10 |
p. 948-953
|
artikel
|
| 5 |
Effect of COVID-19 lockdown on alcohol consumption in patients with pre-existing alcohol use disorder
|
Kim, Jin Un
|
|
|
5 |
10 |
p. 886-887
|
artikel
|
| 6 |
Global hepatitis C elimination: an investment framework
|
Pedrana, Alisa
|
|
|
5 |
10 |
p. 927-939
|
artikel
|
| 7 |
Global prevalence of irritable bowel syndrome according to Rome III or IV criteria: a systematic review and meta-analysis
|
Oka, Priya
|
|
|
5 |
10 |
p. 908-917
|
artikel
|
| 8 |
Global prevalence of irritable bowel syndrome: time to consider factors beyond diagnostic criteria?
|
Vasant, Dipesh H
|
|
|
5 |
10 |
p. 879-880
|
artikel
|
| 9 |
Halo sign and araneid limb-like sign in eosinophilic enteritis
|
Huang, Xing
|
|
|
5 |
10 |
p. 954
|
artikel
|
| 10 |
HCV eradication in chronic kidney disease: ready for prime time?
|
Bruchfeld, Annette
|
|
|
5 |
10 |
p. 880-882
|
artikel
|
| 11 |
IBD in the COVID-19 era: the value of international collaboration
|
Brenner, Erica J
|
|
|
5 |
10 |
p. 887-888
|
artikel
|
| 12 |
Improving global digestive health: the gastroenterologists' role
|
Chudy-Onwugaje, Kenechukwu
|
|
|
5 |
10 |
p. 882-883
|
artikel
|
| 13 |
Integrated care for disorders of gut–brain interaction
|
Chey, William D
|
|
|
5 |
10 |
p. 876-877
|
artikel
|
| 14 |
Laparoscopic ileocaecal resection versus infliximab for terminal ileitis in Crohn's disease: retrospective long-term follow-up of the LIR!C trial
|
Stevens, Toer W
|
|
|
5 |
10 |
p. 900-907
|
artikel
|
| 15 |
Research in brief
|
Baker, Holly
|
|
|
5 |
10 |
p. 889
|
artikel
|
| 16 |
Shifting paradigms in the systemic management of hepatocellular carcinoma
|
Pinato, David J
|
|
|
5 |
10 |
p. 883-885
|
artikel
|
| 17 |
Sofosbuvir plus ribavirin and sofosbuvir plus ledipasvir in patients with genotype 1 or 3 hepatitis C virus and severe renal impairment: a multicentre, phase 2b, non-randomised, open-label study
|
Lawitz, Eric
|
|
|
5 |
10 |
p. 918-926
|
artikel
|
| 18 |
Standard gastroenterologist versus multidisciplinary treatment for functional gastrointestinal disorders (MANTRA): an open-label, single-centre, randomised controlled trial
|
Basnayake, Chamara
|
|
|
5 |
10 |
p. 890-899
|
artikel
|
| 19 |
Surgery versus infliximab for Crohn's disease: should there be a change in clinical practice?
|
Arebi, Naila
|
|
|
5 |
10 |
p. 877-878
|
artikel
|
Tijdschrift beschrijving